<DOC>
	<DOCNO>NCT01077232</DOCNO>
	<brief_summary>Safety Effectiveness adalimumab ( Humira ) Psoriasis Patients Routine Clinical Practice .</brief_summary>
	<brief_title>Documentation Humira Psoriasis Patients Routine Clinical Practice</brief_title>
	<detailed_description>Postmarketing Observational Study Evaluate Work Productivity , Safety Efficacy Humira Treatment Moderate Severe Plaque Psoriasis Daily Clinical Practice.The primary objective PMOS explore change health relate care utilization data evaluation : - number miss work day - number visit doctor 's office - number duration hospitalization - work ability assess efficacy different subgroup - number patient achieve PASI 75 response evaluate safety - documentation analysis adverse event patient subgroups concomitant disease Secondary objective include exploration change quality life measurement , influence age , gender duration disease</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Moderate severe plaque psoriasis adult response systemic therapy ( e.g . cyclosporine , methotrexate PUVA ( photochemical therapy ) ) patient contraindication hypersensitivity therapy Hypersensitivity drug one ingredient ; active tuberculosis severe infection ( e.g . sepsis opportunistic infection ) ; moderate severe cardiac insufficiency</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Moderate Severe Plaque Psoriasis</keyword>
	<keyword>Safety</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Humira</keyword>
	<keyword>Work Productivity</keyword>
</DOC>